About AccufyDx
Accufy Diagnostics develops two sample preparation technologies for next-generation sequencing (NGS) tests on blood. One tags circulating tumor DNA molecules with barcodes. The other enriches the target DNA. They are meant for measurable residual disease (MRD) testing by liquid biopsy and other multiomic uses.
The company is based in Rockville, Maryland. Jeffrey Hung is co-founder and chief executive officer and a co-inventor of both technologies. Both are patent pending in the US and worldwide. Its mission is to save patients through earlier detection of disease. It invites readers to partner with it.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Oct 28, 2026 | $2,000,000fully sold | 3 | $666K | EquityRule 506(b) | Form D ↗ |
| Sep 23, 2025 | Oct 2, 2025 | $200,000fully sold | 1 | $200K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $2,200,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed AccufyDx
Accufy Diagnostics makes sample preparation methods for sequencing-based blood tests that look for measurable residual disease (MRD) in cancer patients. It is based in Rockville, Maryland. Its two methods are patent pending in the US and worldwide. Co-founder and chief executive officer Jeffrey Hung has worked at Vigene Biosciences, GenScript and SABiosciences.
The problem it targets
MRD can help predict whether a tumor will relapse after therapy. Testing for it in blood demands high sensitivity and specificity from sequencing assays. Accufy's case is that two gaps remain. Sensitivity for gene fusions and copy number changes is low. And labs lack sample prep that reads DNA methylation and mutations at the same time.
What the product does
The tagging method puts unique molecular barcodes on both ends of tumor DNA molecules so sequencing can read them. Accufy's case is that it tags both ends of more molecules than any other method. The enrichment method selects target DNA and can finish in as little as 4 hours. It is built to be easy to run in a clinical diagnostic lab and to keep multiomic information in the DNA. The methods can be paired with existing sample prep or enrichment technologies, or used as a turnkey multiomic NGS solution.
Progress so far
Used together, the two methods reach a sensitivity of 0.001% VAF or better, a one-log improvement. The sample prep also preserves epigenetic, RNA and genetic information from patient blood samples. The site does not name customers. It invites readers to partner with the company.
Who backs it
Jeffrey Hung, co-founder and chief executive officer, was general manager and chief commercial officer of Vigene Biosciences. CRL acquired Vigene in July 2021 for about $300 million. In 2016 he led Vigene's purchase of Omnia Biologics. Earlier he was a senior executive at GenScript and helped grow it to its December 2015 IPO. He was also on the management team at SABiosciences, which QIAGEN bought in 2010 for nearly $100 million.
We wrote this summary from public statements by AccufyDx and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on AccufyDx's Form D filed Oct 28, 2026.
